Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Council Members who Treat Colon/Colorectal Cancer

Articles with lock require a subscription to GLG News | Request a free trial
July 31, 2008
Amgen and J & J: Not hurt as much as we had predicted.
Analysis of: Amgen Told to Reword Drug Label | www.nytimes.com
Author: GLG Expert Contributor
Amgens Aranesp sales fell 26% and J & J's Procrit sales fell 23%."Yaron Werber, a biotechnology analyst at Citi Investment Research, estimated that the new label could reduce the use of Aranesp for cancer patients in this country — the drug is also used by people with kidney disease — by an additional...
July 31, 2008
Lung Cancer Screening: Here we go again.
Analysis of: Corrections Weaken Cancer Study | online.wsj.com
Author: GLG Expert Contributor
Lung cancer screening does not appear to prevent death at least in this study.
July 29, 2008
Avastin use in breast ca in the EU? No surprise but does it prolong survival?? Who is the winner??
Analysis of: Roche Files Avastin for Wider Label in EU | www.therapeuticsdaily.com
Author: GLG Expert Contributor
"The filing is supported by data from the phase III Avado trial, which investigated Avastin in combination with docetaxel compared wwith docetaxel alone in the first-line treatment of patients with metastatic breast cancer, Roche said in a statement."
Donald FlemingJuly 24, 2008
EGFR and Non Small Cell Lung Cancer ( NSCLCa)
Analysis of: Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy | jco.ascopubs.org
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Recent BMS subanalysis indicate despite negative trial, EGFR indicates favorable outcome with platinum therapy EGFR will become target for frontline NSCLCa
July 24, 2008
Sorafenib (Bayer) in hepatocellular carcinoma (HCC): already factored in!
Analysis of: Sorafenib in Advanced Hepatocellular Carcinoma | content.nejm.org
Author: GLG Expert Contributor
Sorafenib increases time to progression and median survival in HCC. (World wide a major neoplasm)
July 24, 2008
I know, there is no money in diagnostics, BUT.......
Analysis of: Detection of Mutations in EGFR in Circulating Lung-Cancer Cells | content.nejm.org
Author: GLG Expert Contributor
Peripheral blood in patients with metastatic non small cell lung cancer (NSCLCA) can determine the presence of EGFR mutations in circulating cancer cells that will reveal sensitivity to TKI's- Erbitux (ImClone & BMS), Tarceva (Genentech) and even Iressa (AZ).
July 24, 2008
Erbitux (BMS/ImClone) in Lung Ca: Finally some meat??
Analysis of: Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy | jco.ascopubs.org
Author: GLG Expert Contributor
Lung cancer patients who have increased gene copies of EGFR do better with Cetuximab than do those who do not.
July 21, 2008
Is Alimta (Lilly) the answer? (What is the question?)
Analysis of: Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
Individualizing chemotherapy depending on histology (adenocarcinomas) shows that Alimta/CisPlatin appears to be more convenient and less toxic than its stablemate Gemzar.
July 21, 2008
As if Rituxan (Genentech/Biogen) needed another market?
Analysis of: Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation | content.nejm.org
Author: GLG Expert Contributor
For patients with antibodies that may make renal transplants problematic, Rituxan may make them possible!
July 14, 2008
Notice the US is not part of the discussion?
Analysis of: Glaxo Seeks Guidance From Health Systems | online.wsj.com
Author: GLG Expert Contributor
GSK is discussing drug development with European countries and not the US. Implications???

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next61 to 70 of 660

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T09:45:16.440